Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Income from Continuing Operations (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Income from Continuing Operations data on record, last reported at 40840000.0 in Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 60.44% year-over-year to 40840000.0; the TTM value through Sep 2025 reached 130774000.0, down 94.94%, while the annual FY2024 figure was 84499000.0, 94.65% down from the prior year.
  • Income from Continuing Operations reached 40840000.0 in Q3 2025 per DNTH's latest filing, down from 32622000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 7077000.0 in Q1 2023 and bottomed at 40840000.0 in Q3 2025.
  • Average Income from Continuing Operations over 4 years is 19885600.0, with a median of 17271000.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 69.16% in 2023, then plummeted 165.66% in 2024.
  • A 4-year view of Income from Continuing Operations shows it stood at 10053000.0 in 2022, then fell by 4.57% to 10512000.0 in 2023, then tumbled by 165.66% to 27926000.0 in 2024, then tumbled by 46.24% to 40840000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 40840000.0 in Q3 2025, 32622000.0 in Q2 2025, and 29386000.0 in Q1 2025.